Tempus AI price target raised to $57 from $48 at Loop Capital

Loop Capital analyst Mark Schappel raised the firm’s price target on Tempus AI to $57 from $48 and keeps a Buy rating on the shares. The firm is positive on the company’s innovative healthcare data platform, secular growth theme as a play on precision medicine and genomics becoming the standard of care, and a large customer base of physicians, hospitals, and pharma/biotech companies that leverage and licenses its oncology data, the analyst tells investors in a research note. This is fueling a business that is growing in the low-30% range, Loop states, adding that Tempus AI’s operating margins should scale from the current investment-fueled losses to modest profits in late 2025.